Abstract: The invention relates to the use of microRNA 29 and precursors and mimics thereof for the modulation of tendon injury and the biomechanical properties of tendon. In particular, the invention derives from the finding that synthesis of type 1 collagen in tenocytes is less sensitive to miR-29 than is synthesis of type 3 collagen, thus enabling the balance between the collagen subtypes to be modulated in favor of type 1 collagen, mitigating reduction in biomechanical properties during healing.
Type:
Grant
Filed:
January 14, 2015
Date of Patent:
April 3, 2018
Assignee:
The University Court of the University of Glasgow
Inventors:
Derek Stewart Gilchrist, Neal Lindsay Millar
Abstract: The present invention provides methods to modify the genetic regulation of mammalian tissue, bone, cells or any combination thereof by preferential activation, up-regulation and/or down-regulation. The method comprises steps of tuning the predetermined profiles of one or more time-varying stimulation fields by manipulating the B-Field magnitude, rising slew rate, rise time, falling slew rate, fall time, frequency, wavelength, and duty cycle, and exposing mammalian cells or tissues to one or more tuned time-varying stimulation fields with predetermined profiles. Examples of mammalian cells or tissues are chondrocytes, osteoblasts, osteocytes, osteoclasts, nucleus pulposus, associated tissue, or any combination. The resulted modification on gene regulation of these cells, tissues or bones may promote the retention, repair of and reduction of compromised mammalian cartilage, bone, and associated tissue.
Type:
Grant
Filed:
July 29, 2014
Date of Patent:
February 20, 2018
Assignee:
The United States of America as represented by the National Aeronautics and Space Administration
Inventors:
Thomas J. Goodwin, Linda C. Shackelford
Abstract: A method of using a modified melanoma cell capable of quantification of the effects of MEK inhibitors and CDK4/6 inhibitors in a quantitative, temporal and non-invasive manner both in vitro and in vivo.
Abstract: Methods are provided for the synthesis and secretion of recombinant proteins preferably large mammalian proteins or hetero-multimeric proteins at high levels and for prolonged time in polyploid, preferably diploid yeast. These methods use various mating competent yeast, including Pichia. In a preferred embodiment, a first expression vector is transformed into a first haploid cell; and a second expression vector is transformed into a second haploid cell. The transformed haploid cells, each individually synthesizing a non-identical polypeptide, are identified and then genetically crossed or fused. The resulting diploid strains are utilized to produce and secrete fully assembled and biologically functional hetero-multimeric protein.
Type:
Grant
Filed:
March 24, 2011
Date of Patent:
January 23, 2018
Assignees:
KECK GRADUATE INSTITUTE, ALDERBIO HOLDINGS LLC
Inventors:
James M. Cregg, John Latham, Mark Litton, Randall Schatzman, Ilya Tolstrorukov
Abstract: A method of treating or preventing keratin hyperproliferation skin disorders is set forth. The method includes the administration of an mTOR inhibitor to a subject afflicted with the hyperproliferation disorder. The mTOR inhibitor can be administered to the subject via any means known in the art including oral, topical, and transdermal administration.
Type:
Grant
Filed:
December 8, 2015
Date of Patent:
January 2, 2018
Assignee:
PALVELLA THERAPEUTICS, LLC
Inventors:
Roger Louis Kaspar, Robyn Patricia Hickerson
Abstract: The screening method of the present invention is useful for screening drugs such as insulin secretagogues having an insulin secretagogue activity with minimized side effects (hypoglycemia induction, etc.). The transformant in which a polynucleotide encoding the fusion protein used for the screening method is introduced, the screening kit comprising the transformant, etc. are also useful for screening excellent drugs.
Abstract: Described are methods and means for metabolic engineering and improved product formation by a filamentous micro-organism or a low G+C gram-positive bacterium. Disclosed is that DasR and DasR binding sites play an important and universal role in the control of gene expression in micro-organisms. Based on this finding, provided are multiple useful applications, such as a method for regulating the expression of a gene of interest, a method for controlling metabolism, a method for decreasing undesired expression and many more. Moreover, provided are means that can be used to establish said methods: for example a micro-organism in which the DasR binding site in operable linkage with a particular gene has been modified to obtain increased or decreased expression of a protein (being a desired or undesired protein) encoded by said gene.
Type:
Grant
Filed:
February 14, 2007
Date of Patent:
December 5, 2017
Assignees:
Universiteit Leiden, University of Liège, Friedrich-Alexander-Universität Erlangen-Nürnberg
Inventors:
Sebastien Rigali, Mannfred Friedrich Bruno Titgemeyer, Gilles Philippus Van Wezel
Abstract: The present invention provides genetically modified eukaryotic host cells that produce isoprenoid precursors or isoprenoid compounds. A subject genetically modified host cell comprises increased activity levels of one or more of mevalonate pathway enzymes, increased levels of prenyltransferase activity, and decreased levels of squalene synthase activity. Methods are provided for the production of an isoprenoid compound or an isoprenoid precursor in a subject genetically modified eukaryotic host cell. The methods generally involve culturing a subject genetically modified host cell under conditions that promote production of high levels of an isoprenoid or isoprenoid precursor compound.
Type:
Grant
Filed:
August 4, 2014
Date of Patent:
November 7, 2017
Assignee:
The Regents of the University of California
Inventors:
Jay D. Keasling, James Kirby, Eric M. Paradise
Abstract: This disclosure relates to methods of diagnosing and predicting renal disease, using one, two, or more biomarkers, including sTNFR1, sTNFR2, sFAS, TNF, and IL-6.
Type:
Grant
Filed:
December 9, 2009
Date of Patent:
October 17, 2017
Assignee:
Joslin Diabetes Center, Inc.
Inventors:
Monika A. Niewczas, Andrzej S. Krolewski
Abstract: The present invention relates to a transfer vector for inserting a gene into a genetic locus of a baculovirus sequence. The transfer vector comprises an expression cassette comprising a eukaryotic promoter operably linked to the gene and a bipartite selection cassette. The present invention also relates to methods of using the transfer vector and derived bacmids and baculoviruses.
Type:
Grant
Filed:
November 30, 2015
Date of Patent:
October 3, 2017
Assignee:
London School of Hygiene and Tropical Medicine
Abstract: The present invention provides a method for increasing the expression of MAFA in cells expressing markers characteristic of the pancreatic endocrine lineage comprising the steps of culturing the cells expressing markers characteristic of the pancreatic endocrine lineage in medium comprising a sufficient amount of a cyclin-dependent kinase inhibitor to cause an increase in expression of MAFA.
Abstract: By a genome-wide gene analysis of expression profiles of over 50,000 known or putative gene sequences in peripheral blood, the present inventors have identified a consensus set of gene expression-based molecular biomarkers associated with chronic allograft nephropathy and/or interstitial fibrosis and tubular atrophy CAN/IFTA and subtypes thereof. These genes sets are useful for diagnosis, prognosis, monitoring and/or subtyping of CAN/IFTA.
Type:
Grant
Filed:
July 9, 2010
Date of Patent:
September 5, 2017
Assignee:
The Scripps Research Institute
Inventors:
Daniel Salomon, Sunil M. Kurian, Steven R. Head
Abstract: This invention relates to methods to detect the presence of cancer infiltration of the Central Nervous System (CNS) based on the detection of soluble proteins, preferably, in cerebrospinal fluid samples and vitreous fluid. The invention also relates to kits to perform the methods of the invention.
Type:
Grant
Filed:
July 25, 2012
Date of Patent:
August 29, 2017
Assignee:
UNIVERSIDAD DE SALAMANCA
Inventor:
José Alberto Orfao De Matos Correia E Vale
Abstract: The present invention provides for a recombinant nucleic acid comprising a nucleotide sequence comprising a plurality of constructs, wherein each construct independently comprises a nucleotide sequence of interest flanked by a pair of recombinase recognition sequences. Each pair of recombinase recognition sequences is recognized by a distinct recombinase. Optionally, each construct can, independently, further comprise one or more genes encoding a recombinase capable of recognizing the pair of recombinase recognition sequences of the construct. The recombinase can be an orthogonal (non-cross reacting), site-selective recombinase (OSSR).
Type:
Grant
Filed:
April 15, 2011
Date of Patent:
August 29, 2017
Assignee:
The Regents of the University of California
Inventors:
Joshua M. Gilmore, J. Christopher Anderson, John E. Dueber
Abstract: MicroRNAs (miRNA) are a recently discovered class of small non-coding RNAs (17-14 nucleotides). Due to their function as regulators of gene expression they play a critical role both in physiological and in pathological processes, such as cancer. The present invention provides novel methods for diagnosing prostate cancer based on the determination of specific miRNAs that have altered expression levels in different conditions, e.g. disease states compared to healthy controls.
Type:
Grant
Filed:
August 11, 2015
Date of Patent:
August 29, 2017
Assignee:
Hummingbird Diagnostics GmbH
Inventors:
Andreas Keller, Eckart Meese, Anne Borries, Markus Beier
Abstract: Circular nucleic acid vectors that provide for persistently high levels of protein expression are provided. The circular vectors of the subject invention are characterized by being devoid of expression-silencing bacterial sequences, where in many embodiments the subject vectors include a unidirectional site-specific recombination product hybrid sequence in addition to an expression cassette. Also provided are methods of using the subject vectors for introduction of a nucleic acid, e.g., an expression cassette, into a target cell, as well as preparations for use in practicing such methods. The subject methods and compositions find use in a variety of different applications, including both research and therapeutic applications. Also provided is a highly efficient and readily scalable method for producing the vectors employed in the subject methods, as well as reagents and kits/systems for practicing the same.
Type:
Grant
Filed:
September 8, 2014
Date of Patent:
August 29, 2017
Assignee:
The Board of Trustees of the Leland Stanford Junior University
Abstract: This disclosure provides modified cytosine deaminases (CDs). The disclosure further relates to cells and vector expressing or comprising such modified CDs and methods of using such modified CDs in the treatment of disease and disorders.
Type:
Grant
Filed:
September 4, 2014
Date of Patent:
August 15, 2017
Assignee:
Tocagen Inc.
Inventors:
Harry E. Gruber, Douglas J. Jolly, Omar D. Perez, Christopher R. Logg
Abstract: Described herein are synonymously altered gene sequences which express protein in differing levels within secretory as compared to non-secretory target tissue. An expression cassette comprising an open reading frame (ORF) for a protein under the control of regulatory sequences which direct expression of the product in cell, which ORF has been modified to preferentially increase expression levels in a selected tissue, wherein the modified ORF is characterized by a triplet frequency of any one of Tables 3-12, 16 or 17.
Type:
Grant
Filed:
April 29, 2014
Date of Patent:
August 1, 2017
Assignee:
The Trustees of the University of Pennsylvania
Abstract: The invention provides compositions and methods for the detection of small RNA molecules in a multiplexed reaction. The assays and kits described herein are applicable for the identification, diagnosing, and monitoring of disorders including, but not limited to cancer, developmental and degenerative disease, neurological disorders, and stem cell disorders.
Type:
Grant
Filed:
February 11, 2011
Date of Patent:
July 25, 2017
Assignee:
NanoString Technologies, Inc.
Inventors:
Philippa J. Webster, Lucas M. Dennis, Richard K. Boykin